This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: May 30, 2008
Last updated: December 2, 2010
Last verified: December 2010
The purpose of this study is to learn more about how AZD1305 is handled by the body, i.e the absorption, distribution, metabolism and excretion of AZD1305.

Condition Intervention Phase
Healthy Drug: AZD1305 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open, Randomised, Single-Centre, Crossover Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) After Oral and Intravenous Administration of 14C-labelled and Non-labelled AZD1305 to Healthy Male Volunteers

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Pharmacokinetic variables [ Time Frame: During all dosing visits ]

Secondary Outcome Measures:
  • Adverse events, vital signs, ECG, laboratory variables and physical examination [ Time Frame: During the study ]

Enrollment: 10
Study Start Date: April 2008
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
AZD1305 given as oral solution
Drug: AZD1305
oral solution, single dose
Experimental: B
AZD1305 given as iv infusion
Drug: AZD1305
iv infusion, single dose


Ages Eligible for Study:   35 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers
  • A body mass index (BMI=weight/height2) of 19 to 30 kg/m2

Exclusion Criteria:

  • Potassium outside normal reference values
  • ECG findings outside normal range
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00689247

United Kingdom
Research Site
Macclesfield, Cheshire, United Kingdom
Sponsors and Collaborators
Study Director: Helen Lunde, MD AstraZeneca R&D Mölndal, Sweden
Principal Investigator: Raj Chetty, MBBS, MD AstraZeneca CPU Alderley Park, United Kingdom
  More Information

Responsible Party: Helen Lunde, MD, Medical Science Director, Emerging Arrhythmia and Lipids, AstraZeneca Identifier: NCT00689247     History of Changes
Other Study ID Numbers: D3190C00008
2007-007784-25 (EudraCT No)
Study First Received: May 30, 2008
Last Updated: December 2, 2010

Keywords provided by AstraZeneca:
excretion processed this record on September 19, 2017